Celularity Appoints Rick Gonzalez as Chief Commercial Officer
Celularity appointed Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026, to oversee global commercial strategy for its regenerative medicine portfolio. Gonzalez brings over two decades of experience, including scaling revenue at Spectrum Pharmaceuticals from $7.7 million to $300 million and leading commercialization at Alume Biosciences and Navidea Biopharmaceuticals.
Key figures
- Spectrum revenue end
- $300 million
- Navidea revenue growth
- 2.5x
- Spectrum revenue start
- $7.7 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.